Affiliation:
1. Jiangsu Key Laboratory of Targeted Antiviral Research; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Nanjing Jiangsu Province China
Subject
Organic Chemistry,Spectroscopy,Drug Discovery,Radiology Nuclear Medicine and imaging,Biochemistry,Analytical Chemistry
Reference14 articles.
1. An orally available small-molecule inhibitor of c-MET, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms;Zou;Cancer Res,2007
2. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-MET, in experimental models of anaplastic large-cell lymphoma;Christensen;Mol Cancer Ther,2007
3. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal−epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK);Cui;J Med Chem,2011
4. Case history: Xalkori™ (crizotinib), a potent and selective dual inhibitor of mesenchymal epithelial transition (MET) and anaplastic lymphoma kinase (ALK) for cancer treatment;Cui;Annu Rep Med Chem,2013
5. Applications of stable isotopes in clinical pharmacology;Schellekens;Br J Clin Pharmacol,2011
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献